AI Article Synopsis
- S-1, a 5-FU-based agent, is crucial for treating metastatic extramammary Paget's disease (EMPD), but the expression of key metabolic enzymes in skin cancers has not been previously studied.
- The study aimed to analyze the intratumoral mRNA expression levels of thymidylate synthase (TS), orotate phosphoribosyl-transferase (OPRT), and dihydropyrimidine dehydrogenase (DPD) in EMPD using real-time PCR.
- Findings showed decreased DPD mRNA levels in EMPD compared to normal skin, with a positive correlation between DPD and OPRT mRNA levels, suggesting low DPD expression may play a role in EMPD
Article Abstract
S-1, a 5-fluorouracil (5-FU)-based anti-cancer agent, is an important drug for treating metastatic extramammary Paget's disease (EMPD). Although intratumor expression levels of 5-FU metabolism enzymes have been studied widely in many solid tumors, no studies have examined on the expression levels of thymidylate synthase (TS), orotate phosphoribosyl-transferase (OPRT) or dihydropyrimidine dehydrogenase (DPD) in skin cancers. The aim of this study was to estimate the intratumoral mRNA expression levels of these genes in EMPD by real time PCR. Intratumoral DPD mRNA levels were decreased in EMPD compared to those in normal skin, but its intratumoral DPD mRNA expression levels were not correlated with clinical manifestations. Intratumoral DPD mRNA levels were positively correlated with OPRT mRNA levels in EMPD. Based on these results, low expression of intratumoral DPD mRNA in EMPD may contribute to the pathogenesis of this disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5582/ddt.2017.01022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!